ArticlePediatric dermatology
Association of Nasal and Inhalant Corticosteroids With Pediatric Perioral Dermatitis: A TriNetX Retrospective Cohort Study.
Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although topical corticosteroids are known triggers in the development of perioral dermatitis (PD), investigation into inhalant and nasal corticosteroid preparations, commonly used to manage allergic rhinitis and asthma, remains limited to case series. Using the TriNetX US Collaborative Network, this retrospective cohort study identified pediatric patients (age < 18) with allergic rhinitis or asthma in three groups: corticosteroid nasal/inhalant users, non-steroid nasal/inhalant users, and controls with no nasal/inhalant product use. Patients were propensity score matched 1:1 from 2000 to 2025 with a new diagnosis of PD as the outcome assessed at 6 and 12 months. Corticosteroid nasal/inhalant usage showed an increased association of newly documented PD with the strongest signal occurring within 6 months (RR 3.25, p < 0.0001) remaining persistently elevated although attenuated by 1 year (RR 2.27, p < 0.0001), whereas nonsteroidal preparations showed no such association. Nasal and inhalant containing corticosteroid preparations were clearly associated with PD in this large retrospective database study. They represent a likely underrepresented trigger necessitating clinician attention when encountering new-onset pediatric facial dermatoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.